세계의 류마티스 관절염 치료제 시장(2025년) : 각종 기술 및 시장

The global market for rheumatoid arthritis therapies was valued at $28.5 billion in 2024 and is estimated to increase from $30.2 billion in 2025 to reach $41.1 billion by 2030, at a compound annual growth rate (CAGR) of 6.3% from 2025 through 2030.

The North American market for rheumatoid arthritis therapies was valued at $15.5 billion in 2024 and is estimated to increase from $16.4 billion in 2025 to reach $22.4 billion by 2030, at a CAGR of 6.4% from 2025 through 2030.

The Asia-Pacific market for rheumatoid arthritis therapies was valued at $4.2 billion in 2024 and is estimated to increase from $4.5 billion in 2025 to reach $6.3 billion by 2030, at a CAGR of 7% from 2025 through 2030.

Report Scope

The current report will provide detailed information on therapies for rheumatoid arthritis (RA). This report analyzes the market trends of RA therapies, with the base year for the study set at 2024, estimated for 2025, and forecast between 2026 and 2030, including compound annual growth rate (CAGR) for the forecast period and regional markets. The report will highlight current and future market potential and provide a detailed analysis of the competitive environment as well as regulatory scenarios, drivers, restraints, and opportunities. The report also covers the market shares for key producers.

The market scope in this report is segmented into therapies, including non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), steroids/corticosteroids, biosimilars, and others. It also covers over-the-counter (OTC)- and prescription-based sales channels.

The report covers significant geographical regions: North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America. The regional segmentation will offer a detailed analysis of major countries such as the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia, and India. For market estimates, data will be provided for 2024 as the base year, with forecasts for 2025 through 2030.

The report aims to:

• Analyze RA therapy types.
• Analyze global market size and segmentation.
• Understand market constraints and drivers.
• Provide detailed market forecasts for 2030.
• Assess market shares, competitiveness, and industry structure.
• Identify potential long-term impacts on the market for RA therapies.

Report Includes

• 94 data tables and 51 additional tables
• In-depth analysis of the global markets for rheumatoid arthritis (RA) treatment therapies
• Analyses of global market trends, with revenue data for 2024, estimates for 2025, forecasts for 2026, and projected CAGRs through 2030
• Estimates of the market's current size and revenue prospects, accompanied by a market share analysis based on therapy type, sales channel and region
• Facts and figures pertaining to market dynamics, technological advances, regulations and the impact of macroeconomic factors
• Insights derived from Porter's Five Forces model, as well as global supply chain analysis
• Discussion of the key marketed products and products in different stages of clinical development
• An analysis of patents, and emerging trends and developments in patent activity
• Overview of sustainability trends and ESG developments, with consumer attitudes, and the ESG scores and practices of leading companies
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Company profiles of major players within the industry, including AbbVie Inc., Pfizer Inc., Johnson & Johnson Services Inc., Bristol-Myers Squibb Co., Amgen Inc., and F. Hoffmann-La Roche Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Macroeconomic Factor Analysis
• Impact of U.S. Tariffs on the Pharmaceutical Industry
• Aging Population
• Geopolitical Risks, Trade Wars, and Supply Chain Disruptions
• Increasing Healthcare Expenditures
• Porter's Five Forces Analysis
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Potential for New Entrants
• Threat of Substitutes
• Competitiveness in the Industry

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Increasing Biosimilars for RA Treatment
• Rising Cases of RA
• Increasing Aging Population
• Market Restraints
• Loss of Patent Exclusivity
• Shortage of Rheumatologists
• Side Effects of RA Drugs
• Market Opportunities
• Technological Advances in RA Therapies
• Emerging Targeted Therapies
• Increasing Inorganic Strategies amongst Manufacturers

Chapter 4 Regulatory Landscape

• Overview
• The U.S.
• Biologics
• Biosimilars
• Europe
• Asia-Pacific

Chapter 5 Emerging Technologies and Pipeline Analysis

• Overview
• Artificial Intelligence (AI) and Machine Learning (ML)
• Stem Cell Therapy
• Immunotherapy
• Pipeline Analysis
• Patent Analysis
• Key Takeaways

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Global Market for RA Therapies by Therapy Type
• Key Takeaways
• Disease-modifying Anti-rheumatic Drugs (DMARDs)
• Targeted Synthetic DMARDs/JAK Inhibitors
• Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
• Biosimilars
• Steroids
• Other Drugs
• Global RA Therapies by Sales Channel
• Key Takeaways
• Prescription Drugs
• Over-the-Counter (OTC) Drugs
• Geographic Breakdown
• Global Market for RA Therapies, by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Middle East and Africa (MEA)
• South America

Chapter 7 Competitive Intelligence

• Key Takeaways
• Market Share Analysis
• Company Share Analysis

Chapter 8 Sustainability in the RA Therapies Market: An ESG Perspective

• Introduction to ESG
• Sustainability in the Market for RA Therapies
• ESG Perspective
• Environmental Impact
• Social Impact
• Governance Impact
• ESG Risk Ratings
• Conclusion

Chapter 9 Appendix

• Methodology
• Abbreviations
• Sources
• Company Profiles
• ABBOTT
• ABBVIE INC.
• AMGEN INC.
• BAYER AG
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• GSK PLC.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• PFIZER INC.
• SANOFI
• SWEDISH ORPHAN BIOVITRUM AB
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• VIATRIS INC.